Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study

Autor: Kristina V. Orlova, Mikhail Yu. Fedyanin, Konstantin E. Simanenkov, Aleksandr S. Dergunov, Petr R. Goldshmidt, Aleksandra F. Saydullaeva, Dary V. Bogacheva, Marina A. Yavorskaya, Artur Z. Azanov, Alexander A. Fedenko, Larisa V. Bolotina, Tatyana I. Deshkina, Kseniya G. Babina, Ekaterina A. Kuzevanova, Liudmila G. Zhukova, Polina S. Feoktistova, Natalya I. Polshina, Ekaterina V. Peganova, Valentina E. Shikina, Maksim M. Sobolev, Oleg V. Mironov, Vera A. Vaschenko, Mariya M. Ershova, Agniya O. Mezhueva, Svetlana A. Orlova, Denis A. Tantsyrev, Darya K. Taskina, Antonina A. Teterich, Elena V. Karabina, Yuliya V. Kostalanova, Marina V. Bogacheva, Natalia V. Zhukova, Rashida V. Orlova, Maksim V. Zinkevich, Aleksandr I. Kazmin, Mikhail V. Volkonskiy, Liya M. Voronkova, Anastasiya S. Karpova, Mikhail L. Maleyko, Mariya N. Gorshenina, Elena I. Kryuchkova, Fedor V. Moiseenko, Yuliya I. Murzina, Shamil I. Musin, Andrey N. Ogloblin, Mariya S. Perminova, Regina A. Dumbrava, Sergey A. Emelyanov, Svetlana A. Protsenko, Alexander V. Sultanbaev, Anna V. Tarasova, Elena B. Shakhnovich, Marina V. Demchenkova, Yuliya A. Lozovskaya, Khedi S. Musaeva, Elena M. Pavlova, Roman A. Skotnikov, Vera V. Chernova, Angelina S. Chichkanova, Adina M. Akhmatova, Marina A. Zafirova, Andrey A. Mischenko, Elena N. Ovsienko, Viktoriya A. Petrukhnenko, Oksana A. Syusyukaylova, Yana A. Tyugina, Elena A. Shumilkina, Daniil L. Stroyakovskiy, Aleksandr N. Yurchenkov, Pavel L. Baldin, Anastasiya S. Belova, Olga V. Diduk, Elena A. Konovalova, Lyudmila N. Lebedeva, Yaroslav A. Li, Viktoriya V. Mashtapa, Yana A. Mironenkova, Kristina V. Narovenkova, Olga A. Pavlikova, Elvira L. Parsadanova, Irina S. Pimonova, Anna A. Ruzhnikova, Irina D. Sivunova, Ekaterina P. Soloveva, Maksim I. Sosnin, Toita Kh. Temirsultanova, Makhabbat Zh. Tyulegenova, Aleksandra V. Khodkevich, Nadezhda R. Shakurova, Sureya N. Efendieva, Karine L. Avagimyan, Ekaterina P. Anokhina, Mariya I. Antoshkina, Stanislav M. Borzyanitsa, Samir K. Dzhentemirov, Marina V. Dmitrochenko, Alla V. Zheleznyak, Yuliya V. Komoza, Aleksandr S. Kopanev, Tatyana I. Kornienko, Margarita A. Krasilnikova, Darya A. Lukhmanova, Natalya S. Mazur, Polina M. Markina, Zhargal S. Mitapov, Svetlana N. Osodoeva, Irina A. Prokopenko, Irina M. Radyukova, Madina S. Ramazanova, Alfiya R. Safarova, Mariya A. Safronova, Khalimat M. Khabrieva, Natalya S. Tsygankova, Kseniya V. Chermakova, Tatyana A. Chirkova, Igor V. Samoylenko, Valeria V. Nazarova, Angelina E. Akhmetyanova, Lev V. Demidov

Publikováno v: Современная онкология, Vol 24, Iss 4, Pp 413-425 (2023)

Background. Novel agents immune checkpoint inhibitors fundamentally changed the prognosis for life in patients with metastatic and/or inoperable melanoma. The development, studies, and approval of a new original PD1 inhibitor in Russia in 2020 prompt

Externí odkaz: https://doaj.org/article/0a4a24e511dc43ae8f376adaefc2b0a8